LON:SCLP Scancell (SCLP) Share Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free SCLP Stock Alerts GBX 9.60 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 9.36▼ 9.6050-Day Range 9.54▼ 11.2552-Week Range 7.59▼ 18.30Volume148,719 shsAverage Volume416,756 shsMarket Capitalization£89.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Scancell alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Scancell Stock (LON:SCLP)Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.Read More SCLP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCLP Stock News HeadlinesApril 20, 2024 | americanbankingnews.comScancell (LON:SCLP) Stock Price Crosses Below Two Hundred Day Moving Average of $11.48March 4, 2024 | finance.yahoo.comWith 47% stake, Scancell Holdings plc (LON:SCLP) seems to have captured hedge funds investors' interestApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 23, 2024 | benzinga.comScancell Holdings Stock (OTC:SCNLF), Insider Trading ActivityJanuary 22, 2024 | lse.co.ukScancell Holdings Share ChatJanuary 4, 2024 | proactiveinvestors.comScancell: US investment bank resumes coverage with punchy price targetDecember 18, 2023 | uk.finance.yahoo.comScancell Holdings plc (SCP.F)December 13, 2023 | finance.yahoo.comThe past year for Scancell Holdings (LON:SCLP) investors has not been profitableApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 1, 2023 | proactiveinvestors.comScancell fundraiser brings in £10.7m after it is 'upsized'November 2, 2023 | proactiveinvestors.comAnalysts encouraged by Scancell’s strong year-end trading statementNovember 1, 2023 | proactiveinvestors.comScancell melanoma trial data chosen for poster presentation at SITCOctober 31, 2023 | uk.investing.comScancell makes strong progress with lead immunotherapy assetsOctober 2, 2023 | uk.news.yahoo.comScancell shares are on fire! Should I buy?September 25, 2023 | finance.yahoo.comHedge funds investors are Scancell Holdings plc's (LON:SCLP) biggest bettors and were rewarded after last week's UK£25m market cap gainSeptember 20, 2023 | finance.yahoo.comScancell CEO hails "exciting" high response rate to melanoma treatmentSeptember 19, 2023 | proactiveinvestors.comScancell jumps 23% after trial data; analysts hail resultsSeptember 19, 2023 | proactiveinvestors.comScancell jump 23% after trial data; analysts hail resultsSeptember 7, 2023 | proactiveinvestors.comScancell appoints head of business developmentAugust 23, 2023 | fool.comScancell Plc (LSE: SCLP)July 31, 2023 | proactiveinvestors.comScancell passes 'important milestone' with cancer trial expansionJuly 11, 2023 | finance.yahoo.comScancell Holdings "well-financed" and continuing to pursue dealsJuly 6, 2023 | finance.yahoo.comInvesting in Scancell Holdings (LON:SCLP) three years ago would have delivered you a 146% gainJune 2, 2023 | proactiveinvestors.comScancell updates on progress ahead of ASCO poster presentationApril 18, 2023 | proactiveinvestors.comScancell says its Head of Clinical Operations to make AACR poster presentationMarch 13, 2023 | proactiveinvestors.comScancell has no exposure to Silicon Valley Bank, company assures stakeholdersMarch 13, 2023 | proactiveinvestors.comScancell Holdings had no exposure to Silicon Valley Bank, company assures stakeholdersSee More Headlines Receive SCLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/31/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SCLP CUSIPN/A CIKN/A Webwww.scancell.co.uk Phone+44-115-8231863FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-9,530,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-269.84% Return on Assets-37.22% Debt Debt-to-Equity Ratio61.41 Current Ratio8.63 Quick Ratio13.01 Sales & Book Value Annual Sales£5.27 million Price / Sales16.64 Cash FlowGBX 1.20 per share Price / Cash Flow7.86 Book ValueGBX (1) per share Price / Book-9.45Miscellaneous Outstanding Shares927,820,000Free FloatN/AMarket Cap£87.68 million OptionableNot Optionable Beta0.34 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesProf. Lindy Gillian Durrant Ph.D. (Age 67)Founder, CEO, Chief Scientific Officer & Director Comp: $369.12kDr. Sally Elizabeth Adams (Age 63)Executive Officer Comp: $253.51kMr. Sathijeevan Nirmalananthan (Age 38)CFO & Director Dr. Samantha Paston Ph.D.Head of Translational ResearchDr. Adrian Parry Ph.D.Head of ManufacturingDr. Mandeep SehmiHead of Business DevelopmentDr. Callum ScotthasbeenHead of DevelopmentMr. Keith Charles GreenCompany SecretaryMore ExecutivesKey CompetitorsMereo BioPharma Group plc (MPH.L)LON:MPHFaron Pharmaceuticals OyLON:FARNFutura MedicalLON:FUMOpen OrphanLON:ORPHVerseonLON:VSNView All Competitors SCLP Stock Analysis - Frequently Asked Questions How have SCLP shares performed in 2024? Scancell's stock was trading at GBX 10.50 at the start of the year. Since then, SCLP shares have decreased by 8.6% and is now trading at GBX 9.60. View the best growth stocks for 2024 here. How were Scancell's earnings last quarter? Scancell Holdings plc (LON:SCLP) released its earnings results on Friday, January, 31st. The company reported ($0.56) earnings per share (EPS) for the quarter. What other stocks do shareholders of Scancell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU). How do I buy shares of Scancell? Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SCLP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scancell Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
